

Crystalvue Medical Corporation
Notice of 2023 Annual General Shareholders' Meeting
(Summary Translation)

- I. The 2023 Annual General Shareholders' Meeting (the "Meeting") will be held at 9:00 a.m. on Thursday, June 29, 2023 at Fullon Hotel Taoyuan (No. 200, Section 1, Dashingshi Road, Taoyuan District, Taoyuan City, Taiwan, Republic of China (R.O.C.)).

Agenda

1. Report Items

- (1) 2022 Business Report.
- (2) Audit Committee's Review Report of 2022.
- (3) Remuneration distribution to employees and directors for 2022.
- (4) Implementation of Treasury Stocks Buyback.
- (5) Amendment to the "Plan of Share Repurchase and Transferring to the Employees".

2. Proposed Resolutions

- (1) 2022 Business Report and Financial Statements.
- (2) Distribution of 2022 Profits.

3. Discussions and Election

- (1) Proposal for a new share issue through capitalization of earnings.
- (2) Amendment to the "Rules of Procedure for Shareholders Meetings".
- (3) Amendment to the "Procedure for the Acquisition and Disposition of Assets" and "The Procedure of Derivate Instrument".
- (4) Transfer of treasury stocks to employees at a price lower than the actual average repurchase price.
- (5) To elect one Director to fill the vacancy.
- (6) Proposal of Release the Prohibition on new Director from Participation in Competitive Business.
- (7) Private placement of common stock.

4. Other Business and Special Motion

- II. The proposal for distribution of 2022 earnings adopted at the meeting of the Board of Directors is as follows:

Cash dividends: the proposed dividend is NT\$ 2.40 per share.

Stock dividends: the proposed dividend is NT\$ 0.50 per share.

III. The company should elect 1 Director. The list of candidate for the nomination system for the Director: The Director is: Chong-Yi Li .

To view related information such as educational background / work experience, please visit Market Observation Post System. (<http://mops.twse.com.tw>)

IV. Under the premise of the resolution in accordance with Article 209 of the Company Act, hereby proposes for the removal of restrictions on non-competition obligation for newly elected directors and their representatives.

For the concurrent positions of newly elected directors, please refer to the meeting agenda.

V. We hereby issue this letter together with an Attendance Notice of the Meeting and a Proxy Attendance Form. To attend the Meeting in person, please sign or stamp on the Attendance Notice and register in person at the Meeting on the scheduled meeting date; to attend by proxy, please fill out and return the Proxy Attendance Form. In order to be valid, the Proxy Attendance Form shall be delivered to the Stock Transfer Agency Department of Mega Securities Co., Ltd. five days prior to the Meeting.

VI. The Company will compile and post a general list of information on calls for proxies, if any, 30 days before the Meeting, on the Securities & Futures Institute website (<http://free.sfi.org.tw>). Investors may search information on the above site.

VII. Should there be items related to article 172 of the Company Act, Article 26-1 and 43-6 of Securities and Exchange Act or other relevant laws and regulations will be posted on the Market Observation Post System under icon: Electronic Books / Shareholders' meetings / Stock code 6527 / Year 2023 (<https://emops.twse.com.tw>) and Company website.

VIII. Of this Meeting, the statistic verification agency of the Power of Attorney will be Mega Securities Co., Ltd. (Stock Transfer Agency Department).

IX. Voting rights for the Meeting can be exercised via electronic form during the period from May 30, 2023 to June 26, 2023. Please access "Shareholder e-voting" at the website of Taiwan Depository & Clearing Corporation

(<https://www.stockvote.com.tw>).

X. No souvenir will be offered in the Meeting.

Sincerely,

Board of Directors
Crystalvue Medical Corporation